Erratum: Development of a Mimotope Vaccine Targeting the Staphylococcus aureus Quorum Sensing Pathway (PLoS ONE (2014) 9:11 (e111198) DOI: 10.1371/journal.pone.0111198);Development of a mimotope vaccine targeting the Staphylococcus aureus quorum sensing pathway

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  O'Rourke, John P ^a   Daly, Seth M ^a   Triplett, Kathleen D ^a   Peabody, David ^a   Chackerian, Bryce ^a   Hall, Pamela R ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AUTOINDUCING PEPTIDE 4; EPITOPE; MIMOTOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AP4 24H11; PEPTIDE; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; AGRD PROTEIN, STAPHYLOCOCCUS; BACTERIAL PROTEIN; BACTERIAL VACCINE; BIOMIMETIC MATERIAL; CYCLOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL VIRULENCE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; FEMALE; GENE CONTROL; GENE EXPRESSION; MONOTHERAPY; MOUSE; NONHUMAN; OPERON; PASSIVE IMMUNIZATION; QUORUM SENSING; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SKIN NECROSIS; STAPHYLOCOCCUS AUREUS; ULCER; UPREGULATION; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; CYTOLOGY; FEASIBILITY STUDY; IMMUNOLOGY;

STAPHYLOCOCCUS AUREUS;

AMINO ACID SEQUENCE; ANIMALS; BACTERIAL PROTEINS; BACTERIAL VACCINES; BIOMIMETIC MATERIALS; EPITOPES; FEASIBILITY STUDIES; FEMALE; MICE; PEPTIDES, CYCLIC; QUORUM SENSING; STAPHYLOCOCCUS AUREUS;

EID: 84915750917     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0118160     Document Type: Erratum

References (46)

1. Chackerian B (2007) Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines 6: 381-390.
2. Tumban E, Peabody J, Peabody DS, Chackerian B (2011) A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS One 6: e23310.
3. Tissot AC, Renhofa R, Schmitz N, Cielens I, Meijerink E, et al. (2010) Versatile virus-like particle carrier for epitope based vaccines. PLoS ONE 5: e9809.
4. Jennings GT, Bachmann MF (2008) The coming of age of virus-like particle vaccines. Biol Chem.
5. Mihailova M, Boos M, Petrovskis I, Ose V, Skrastina D, et al. (2006) Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV). Vaccine 24: 4369-4377.
6. Caldeira JC, Peabody DS (2011) Thermal stability of RNA phage virus-like particles displaying foreign peptides. J Nanobiotechnology 9: 22.
7. Peabody DS, Manifold-Wheeler B, Medford A, Jordan SK, do Carmo Caldeira J, et al. (2008) Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2. J Mol Biol 380: 252-263.
8. Caldeira JC, Peabody DS (2007) Stability and assembly in vitro of bacteriophage PP7 virus-like particles. J Nanobiotechnology 5: 10.
9. Caldeira Jdo C, Medford A, Kines RC, Lino CA, Schiller JT, et al. (2010) Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine 28: 4384-4393.
10. Chackerian B, Caldeira Jdo C, Peabody J, Peabody DS (2011) Peptide epitope identification by affinity selection on bacteriophage MS2 virus-like particles. J Mol Biol 409: 225-237.
11. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, et al. (2006) Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355: 666-674.
12. Wright JS 3rd, Jin R, Novick RP (2005) Transient interference with staphylococcal quorum sensing blocks abscess formation. Proc Natl Acad Sci U S A 102: 1691-1696.
13. Montgomery CP, Boyle-Vavra S, Daum RS (2010) Importance of the global regulators Agr and SaeRS in the pathogenesis of CA-MRSA USA300 infection. PLoS One 5: e15177.
14. Wang R, Braughton KR, Kretschmer D, Bach TH, Queck SY, et al. (2007) Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 13: 1510-1514.
15. Park J, Jagasia R, Kaufmann GF, Mathison JC, Ruiz DI, et al. (2007) Infection control by antibody disruption of bacterial quorum sensing signaling. Chem Biol 14: 1119-1127.
16. Novick RP, Geisinger E (2008) Quorum sensing in staphylococci. Annu Rev Genet 42: 541-564.
17. Cheung GY, Wang R, Khan BA, Sturdevant DE, Otto M (2011) Role of the accessory gene regulator agr in community-associated methicillin-resistant Staphylococcus aureus pathogenesis. Infect Immun 79: 1927-1935.
18. Kobayashi SD, Malachowa N, Whitney AR, Braughton KR, Gardner DJ, et al. (2011) Comparative analysis of USA300 virulence determinants in a rabbit model of skin and soft tissue infection. J Infect Dis 204: 937-941.
19. Inoshima N, Wang Y, Bubeck Wardenburg J (2012) Genetic requirement for ADAM10 in severe Staphylococcus aureus skin infection. J Invest Dermatol 132: 1513-1516.
20. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney AR, et al. (2010) Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis 202: 1050-1058.
21. Tkaczyk C, Hua L, Varkey R, Shi Y, Dettinger L, et al. (2012) Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency. Clin Vaccine Immunol 19: 377-385.
22. Rothfork JM, Timmins GS, Harris MN, Chen X, Lusis AJ, et al. (2004) Inactivation of a bacterial virulence pheromone by phagocyte-derived oxidants: new role for the NADPH oxidase in host defense. Proc Natl Acad Sci U S A 101: 13867-13872.
23. Peterson MM, Mack JL, Hall PR, Alsup AA, Alexander SM, et al. (2008) Apolipoprotein B Is an innate barrier against invasive Staphylococcus aureus infection. Cell Host Microbe 4: 555-566.
24. Hall PR, Elmore BO, Spang CH, Alexander SM, Manifold-Wheeler BC, et al. (2013) Nox2 modification of LDL is essential for optimal apolipoprotein Bmediated control of agr type III Staphylococcus aureus quorum-sensing. PLoS Pathog 9: e1003166.
25. Schlievert PM, Case LC, Nemeth KA, Davis CC, Sun Y, et al. (2007) Alpha and beta chains of hemoglobin inhibit production of Staphylococcus aureus exotoxins. Biochemistry 46: 14349-14358.
26. Pynnonen M, Stephenson RE, Schwartz K, Hernandez M, Boles BR (2011) Hemoglobin promotes Staphylococcus aureus nasal colonization. PLoS Pathog 7: e1002104.
27. Kaufmann GF, Park J, Mayorov AV, Kubitz DM, Janda KD (2011) Generation of quorum quenching antibodies. Methods Mol Biol 692: 299-311.
28. Kirchdoerfer RN, Garner AL, Flack CE, Mee JM, Horswill AR, et al. (2011) Structural basis for ligand recognition and discrimination of a quorumquenching antibody. J Biol Chem 286: 17351-17358.
29. Malachowa N, Kobayashi SD, Braughton KR, DeLeo FR (2013) Mouse model of Staphylococcus aureus skin infection. Methods Mol Biol 1031: 109-116.
30. Malone CL, Boles BR, Lauderdale KJ, Thoendel M, Kavanaugh JS, et al. (2009) Fluorescent reporters for Staphylococcus aureus. J Microbiol Methods 77: 251-260.
31. Sully EK, Malachowa N, Elmore BO, Alexander SM, Femling JK, et al. (2014) Selective chemical inhibition of agr quorum sensing in Staphylococcus aureus promotes host defense with minimal impact on resistance. PLoS Pathog 10: e1004174.
32. Bose JL, Daly SM, Hall PR, Bayles KW (2014) Identification of the Staphylococcus aureus vfrAB operon, a novel virulence factor regulatory locus. Infect Immun 82: 1813-1822.
33. Munoz-Planillo R, Franchi L, Miller LS, Nunez G (2009) A critical role for hemolysins and bacterial lipoproteins in Staphylococcus aureus-induced activation of the Nlrp3 inflammasome. J Immunol 183: 3942-3948.
34. Craven RR, Gao X, Allen IC, Gris D, Bubeck Wardenburg J, et al. (2009) Staphylococcus aureus alpha-hemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells. PLoS One 4: e7446.
35. Berube BJ, Bubeck Wardenburg J (2013) Staphylococcus aureus alpha-toxin: nearly a century of intrigue. Toxins (Basel) 5: 1140-1166.
36. Cho JS, Guo Y, Ramos RI, Hebroni F, Plaisier SB, et al. (2012) Neutrophilderived IL-1beta is sufficient for abscess formation in immunity against Staphylococcus aureus in mice. PLoS Pathog 8: e1003047.
37. Bhakdi S, Muhly M, Korom S, Hugo F (1989) Release of interleukin-1 beta associated with potent cytocidal action of staphylococcal alpha-toxin on human monocytes. Infect Immun 57: 3512-3519.
38. Bubeck Wardenburg J, Schneewind O (2008) Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 205: 287-294.
39. Hua L, Hilliard JJ, Shi Y, Tkaczyk C, Cheng LI, et al. (2014) Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother 58: 1108-1117.
40. Brady CS, Bartholomew JS, Burt DJ, Duggan-Keen MF, Glenville S, et al. (2000) Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens 55: 401-411.
41. Fowler VG Jr, Proctor RA (2014) Where does a Staphylococcus aureus vaccine stand? Clin Microbiol Infect 20 Suppl 5: 66-75.
42. Kaufmann GF, Park J, Janda KD (2008) Bacterial quorum sensing: a new target for anti-infective immunotherapy. Expert Opin Biol Ther 8: 719-724.
43. Cheung GY, Otto M (2012) The potential use of toxin antibodies as a strategy for controlling acute Staphylococcus aureus infections. Expert Opin Ther Targets 16: 601-612.
44. Ragle BE, Bubeck Wardenburg J (2009) Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect Immun 77: 2712-2718.
45. Adhikari RP, Karauzum H, Sarwar J, Abaandou L, Mahmoudieh M, et al. (2012) Novel structurally designed vaccine for S. aureus alpha-hemolysin: protection against bacteremia and pneumonia. PLoS One 7: e38567.
46. Foletti D, Strop P, Shaughnessy L, Hasa-Moreno A, Casas MG, et al. (2013) Mechanism of action and in vivo efficacy of a human-derived antibody against Staphylococcus aureus alpha-hemolysin. J Mol Biol 425: 1641-1654.